News

Pilot study finds maternal dairy intake associated with lower levels of select human milk lipids, with unclear implications for infant health.

Jon Farber, MD, shares his thoughts on outpatient management for some febrile patients with sickle cell disease.

FDA testing of 312 infant formula samples found low or undetectable levels of contaminants, supporting safety and ongoing monitoring efforts.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the March/April 2026 issue of Contemporary Pediatrics, focused on nutrition.

The FDA cleared a generic Infuvite Pediatric injection for children receiving parenteral nutrition, adding a new option for hospital supply.

New AAP guideline replaces “failure to thrive” with “faltering weight,” emphasizing standardized diagnosis and targeted, less invasive care.

The FDA approved Breztri Aerosphere as the first single-inhaler triple therapy for asthma maintenance in patients 12 years and older.

AbbVie filed an sNDA for upadacitinib to treat severe alopecia areata in adults and adolescents based on phase 3 UP-AA trial results.

Jon Farber, MD, shares his thoughts on the benefits of continuous intrathecal baclofen therapy in cerebral palsy.

FDA clearance is being sought for roflumilast cream for infants 3 months and older with mild to moderate atopic dermatitis.

Autism diagnoses by primary care providers vary widely by region and state, highlighting disparities in access to specialty care.

Maternal RSV vaccination and nirsevimab were linked to lower infection rates and reduced severity in infants younger than 6 months.

Large trial finds balanced fluids and saline yield similar outcomes in pediatric septic shock, reinforcing flexible resuscitation practices.

Natasha Wade, PhD, highlights longitudinal data showing that adolescent cannabis exposure may blunt neurocognitive development over time.

MMR coverage remained below herd immunity 20 months after an Ohio outbreak, with minimal gains and persistent disparities in children.

Data show children in disaster-displaced households have greater mental health needs but are less likely to receive complete care vs nondisplaced peers.

The FDA approved lunsotogene parvec-cwha as the first gene therapy for genetic hearing loss caused by biallelic OTOF variants.

Fewer pediatric lung transplants are expected worldwide because of advances in cystic fibrosis therapies, but remaining cases are becoming more complex.

The FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria, making it the first biologic for young pediatric CSU patients.

FDA expands teplizumab to children aged ≥1 year with stage 2 T1D, enabling earlier intervention to delay progression to insulin dependence.

A national poll highlights low physical activity rates among young adults aged 18 to 25 years.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

In a longitudinal pediatric cohort, elexacaftor/tezacaftor/ivacaftor was associated with increased vitamin D levels and altered vitamin A supplementation response.

Real-world data show pediatric hidradenitis suppurativa treatment relies on antibiotics, with delayed escalation and demographic differences in timing.

New findings highlight elevated secondary cancer risks in adolescent and young adult survivors, underscoring the need for treatment-specific screening strategies.

Marisol Betensky, MD, outlines how dynamic risk evaluation and innovative trial designs can improve anticoagulation decision-making in pediatric VTE care.

A pilot study finds diverse arthritis patterns and high metabolic comorbidity burden in idradenitis suppurativa, with IL-17 inhibitors showing improved outcomes.

Marisol Betensky, MD outlines how institutions can implement risk-stratified guidelines while balancing thrombosis prevention, bleeding risk, and limited evidence.